New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTCBRL, BCEI, VAR, MDCO, DKS, ALKS, ARQL, ARIAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:01 EDTMDCOThe Medicines Co., SciClone establish strategic partnership
The Medicines Company (MDCO) and SciClone Pharmaceuticals (SCLN) announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company: ANGIOMAX for Injection, an anticoagulant indicated in patients undergoing percutaneous coronary intervention with provisional use of glycoprotein IIb/IIIa inhibitor and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome undergoing PCI. A Phase 3 registration trial was completed in China and is currently under review by the China Food and Drug Administration for marketing approval. CLEVIPREX Injectable Emulsion, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable. The clinical trial application for China was filed in 2013. Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market excluding Hong Kong and Macau. SciClone has also agreed to assist in the China registration process for both products. Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include the following additional payments to The Medicines Company: an upfront payment; a product support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5M.
December 17, 2014
12:12 EDTVARVarian Medical announces intention to acquire MeVis Medical Solutions AG
Subscribe for More Information
06:14 EDTALKSAlkermes price target raised to $72 from $60 at Citigroup
Subscribe for More Information
December 15, 2014
07:02 EDTALKSAlkermes announces initiation of Phase 1 aripiprazole lauroxil study
Subscribe for More Information
December 11, 2014
10:13 EDTARIAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
09:16 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTARIAARIAD downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded ARIAD to Underperform from Neutral. The firm said Iclusig launch metrics are weak and expects it to remain a last option for CML patients with specific resistant mutations or failure with other therapies. Price target lowered to $6 from $8.
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
06:14 EDTARIAARIAD downgraded to Underperform from Neutral at Credit Suisse
Subscribe for More Information
December 9, 2014
09:10 EDTARIAARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
07:37 EDTARIAARIAD announces safety, efficacy follow-up data on Iclusig
Subscribe for More Information
07:36 EDTARIAARIAD says Iclusig shows anti-leukemic activity in long-term follow up data
ARIAD Pharmaceuticals announced long-term follow up data from the Phase 1 trial of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The study now shows that with a median follow-up of four years in chronic phase CML patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients with 72 percent having a major cytogenetic response, 65 percent having a complete cytogenetic response and 56 percent having a major molecular response. Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events. These data were featured in a poster presentation on December 8 at the 56th Annual Meeting of the American Society of Hematology taking place in San Francisco.
December 8, 2014
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information
09:20 EDTCBRLCracker Barrel price target raised to $150 from $120 at Argus
Subscribe for More Information
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information
07:40 EDTBCEIMany E&P target prices lowered at SunTrust
Subscribe for More Information
07:36 EDTARIAARIAD: Iclusig demonstrates anti-leukemic activity in patents in Phase 2 trial
Subscribe for More Information
December 5, 2014
10:35 EDTALKSHigh option volume stocks
High option volume stocks: NOAH FRAN BIG GREK KEY VIAB STRZ ALKS QTWW ONNN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use